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chemotactic protein-1 and transforming growth
factor-1 in healing rat vein grafts
Randal A. Wolff, PhD,a Jeffrey J. Tomas, BS,a Debra A. Hullett, PhD,a V. Emily Stark, MS,a Nico van
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Objective: We previously showed that treatment with liposomally encapsulated dichloromethylene bisphosphonate
reduces intimal hyperplasia development and macrophage accumulation in a rat epigastric vein to femoral artery model of
intimal hyperplasia. Our objective in this study was to determine the effect of liposomally encapsulated dichloromethylene
bisphosphonate on the expression of two cytokines essential to neointimal development, monocyte chemotactic protein-1
(MCP-1) and transforming growth factor-1 (TGF-).
Methods: We injected rats both 2 days preoperatively and 2 weeks postoperatively with liposomally encapsulated
dichloromethylene bisphosphonate (Lip-Clod), liposomally encapsulated phosphate-buffered saline solution (Vector), or
phosphate-buffered saline solution (PBS), and harvested the grafts at 1 and 4 weeks. In the perianastomotic region,
MCP-1 and TGF- protein expression in the total graft cross-section and in the neointima was determined with
immunohistochemistry. In whole-graft lysates, MCP-1 and TGF- protein were determined with an enzyme-linked
immunosorbent assay, and messenger RNA expression was determined with reverse transcription quantitative polymerase
chain reaction.
Results: Lip-Clod treatment reduced intimal hyperplasia when compared with Vector or PBS treatment. These reductions
were significant (P < .05) at both time points. When compared with the PBS treatment, at 1 week but not at 4 weeks
Lip-Clod reduced both MCP-1 and TGF- protein (P < .01 and P < .006) in the perianastomotic region of vein grafts.
In whole-graft lysates, no significant difference was seen in MCP-1 protein at either time point; however, TGF- protein
expression was significantly reduced at both 1 and 4 weeks (P .02 and P .004). Message analysis in whole-graft lysates
at 1 week showed that MCP-1 message expression increased in the Lip-Clod group compared with the PBS group (P 
.02), but no significant differences among groups for TGF-message levels. Results with Vector were often intermediate
to results with Lip-Clod and PBS.
Conclusion: The major effect of Lip-Clod treatment on TGF- and MCP-1 protein levels in the perianastomotic region
is observed at 1 week, and macrophage depletion with Lip-Clod inhibits graft neointimal hyperplasia and TGF- protein
expression in whole-graft lysates at 1 and 4 weeks. These results support the concept that the infiltrating macrophages
contribute a significant portion of the cytokines that facilitate intimal hyperplasia and that reducing these cytokines early
after grafting influences the development of intimal hyperplasia at later time points. (J Vasc Surg 2004;39:878-88.)
Clinical Relevance: All vascular surgeons have patients who have undergone a technically satisfying vein graft, only to
have the bypass fail during the first year due to perianastomotic intimal hyperplasia (IH). We hypothesize that vein graft
IH is analogous to aberrant wound healing. Central to wound healing is the recruitment of macrophages with their
cytokines. This work raises the question whether clinical strategies designed to either decrease macrophages or the cytokines
released by macrophages at the time of vein graft placement will be efficacious for limiting the development of IH.Autologous vein grafts are a common surgical alterna-
tive for many types of vascular reconstruction; however, the
failure rate of these grafts after 1 year approaches 20%.1
Failure of these grafts is due to the development of intimal
hyperplasia, a fibroproliferative thickening of the neointima
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doi:10.1016/j.jvs.2003.11.039878that often leads to stenosis. It has been proposed that
intimal hyperplasia begins as a wound healing response, and
continues into a condition of unchecked cellular prolifera-
tion and extracellular matrix deposition. Central to the
wound healing response are activated macrophages and the
cytokines they release.2 Activated macrophages infiltrate
vein grafts initially as part of an inflammatory response, yet
they remain within the vein wall during the later stages of
intimal hyperplasia development.3 Macrophage and mono-
cyte recruitment to the site of injury in vein bypass grafts is
mediated by monocyte chemotactic protein-1 (MCP-1), a
strong chemokine for macrophages and monocytes that is
secreted by smooth muscle cells (SMCs), endothelial cells,
fibroblasts, and leukocytes, all of which are present in vein
grafts.3 Upregulation of MCP-1 messenger RNA expres-
sion and of MCP-1 protein expression is consistent with
intimal hyperplasia development in rat vein grafts.3
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functional cytokine important in normal growth and devel-
opment, and in inflammation, wound healing, and tumor-
igenesis. Because TGF- is a potent stimulator of vascular
SMCs4 and fibroblast5 extracellular matrix synthesis, it is a
major contributor to the development of intimal hyperpla-
sia.6 In addition, TGF- is a bifunctional modulator of cell
death that exerts a proapoptotic influence on endothelial
cells and is antiapoptotic for vascular SMCs.7 This factor
can behave in both an autocrine and a paracrine fashion.8
Cellular sources of TGF- include platelets,9 endothelial
cells,10 SMCs,11,12 myofibroblasts,13-15 macrophages,16,17
neutrophils,18 and T lymphocytes.19 All of these cells par-
ticipate in the remodeling of the healing vein graft,20 and
may be contributing bioactive TGF- during intimal hy-
perplasia development.
When macrophages are depleted in animal models
there is suppression of intimal hyperplasia, with resumption
of the process as macrophages repopulate the vein graft.21
Danenberg et al22 showed that, in a balloon injury model,
in addition to a reduction in intimal hyperplasia, macro-
phage depletion also reduces the inflammatory mediator
interleukin-1. In this study we show that, coincident with
the reduction in intimal hyperplasia, depletion of macro-
phages reduces the amount of MCP-1 and TGF- in the
perianastomotic region of the vein graft at 1 week and the
amount of TGF- in the whole graft at 1 and 4 weeks. This
result supports the hypothesis that the infiltrating macro-
phages contribute a significant portion of the cytokines that
facilitate intimal hyperplasia and that reducing these cyto-
kines early after grafting influences the development of
intimal hyperplasia later.
MATERIAL AND METHODS
Treatment, vein grafting, and harvest. Male Lewis
rats (Harlan, Indianapolis, Ind) weighing 350 to 450 g
were used in this study. Dichloromethylene bisphospho-
nate (clodronate; a gift from Roche Diagnostics, Mann-
heim, Germany) was encapsulated in multilamellar lipo-
somes as described.23 Two days before grafting, 4 mL of
liposomally encapsulated dichloromethylene bisphospho-
nate (Lip-Clod) was slowly injected intravenously under
isoflurane (Abbott, North Chicago, Ill) gas anesthesia. To
control for the injection procedure and blood volume
change, a control group of animals was treated with an
equivalent volume of phosphate-buffered saline solution
(PBS). As a control for liposomally encapsulated dichlo-
romethylene bisphosphonate versus the effects of lipo-
somes alone, liposomal PBS (Vector) was used in a second
set of control animals.
Free clodronate will not easily pass phospholipid bilay-
ers of liposomes and cell membranes, but liposomes are
phagocytosed by macrophages. After disruption of the
phospholipid bilayers of the liposomes by lysosomal phos-
pholipases in the macrophage, the drug, which is dissolved
in the aqueous compartments between the liposomal bilay-
ers, is released into the cell. The clodronate is accumulated
intracellularly, and after exceeding a threshold concentra-tion the cell is irreversibly damaged and dies by apoptosis.
Free clodronate, for example, released from dead macro-
phages, has an extremely short half-life in the circulation. It
is removed from the circulation by the renal system.24
Vein implantation was performed according to pub-
lished methods.25 In brief, an 8-mm section of epigastric
vein was excised and interposed into a 3-mm defect in the
femoral artery. Each anastomosis was completed with 8 to
10 interrupted sutures of 10-0 nylon. Because the macro-
phage depletion effect has been determined to last 2
weeks,21 each animal to be harvested at 4 weeks received a
second injection (4 mL) according to their treatment at 2
weeks after surgery. At 1 or 4 weeks after surgery, grafts, 5
mm of vein from the middle of the contralateral nongrafted
epigastric vein, and 5 mm of spleen (from the middle of the
spleen longitudinally) were harvested and processed for
analysis. The harvested grafts were used for histologic ex-
amination, immunohistochemical staining, enzyme-linked
immunosorbent assay (ELISA), and mRNA analysis with
quantitative polymerase chain reaction (Q-PCR). Proce-
dures were approved by the Research Animal Resources
Center at the University of Wisconsin, Madison. Animal
care complied with the Guide for the Care and Use of
Laboratory Animals.26
Histologic examination. Grafted and nongrafted
vein and spleen specimens were fixed in 10% formalin and
stored at 4°C overnight. On the following day tissue spec-
imens were soaked in 50% ethyl alcohol for 30 minutes at
room temperature, then stored in 70% ethyl alcohol in
preparation for paraffin embedding, as previously de-
scribed.25 Five-micrometer sections of spleen and vein
specimens were cut, and placed on glass slides. The spleen
and nongrafted vein were sectioned serially. The proximal
regions of vein grafts, which exhibit the most intimal hy-
perplasia, were sectioned at 500-m intervals, as de-
scribed.3 The vein graft was sectioned, starting 3 mm from
the proximal anastomosis toward the proximal anastomo-
sis. The results reported for each graft, nongrafted vein, and
spleen are an average of measurements from three sections.
Sections were deparaffinized extensively, and rehydrated in
graded ethanol solutions. Vein graft sections were then
stained with hematoxylin-eosin for morphometric analyses.
Immunohistochemistry. Immunohistochemical
staining was performed as described,3 with slight modifica-
tions. After deparaffinization and rehydration, graft sec-
tions to be stained with MCP-1 were incubated in 1X TE
(10 mmol/L Tris buffer, 1 mmol/L ethylenediamine tet-
raacetic acid, pH 8) in a 95°C water bath for 1 hour to
enhance antigen retrieval.27-29 MCP-1–specific rabbit
polyclonal antibody (PeproTech; 2.5 g/mL) and TGF-
–specific mouse monoclonal antibody (R&D Systems; 5
g/mL) were used for the primary antibodies. To ensure
specificity of immunohistochemistry, parallel staining was
performed with a negative control antibody not reactive to
rat antigens, but the same immunoglobulin G (IgG) sub-
type (IgG1 for mouse monoclonal) or from the same spe-
cies (for rabbit polyclonal) as the cytokine-specific primary
antibody. Primary antibody specificity was tested with var-
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primary antibody and color development was performed
with the Universal DAKO LSAB 2 Kit, peroxidase for use
on RAT Specimens (DAKO), and DAKO Liquid DAB
Large Volume Substrate-Chromogen System, according to
the manufacturer’s instructions. Immunostained sections
were used for quantitative analysis of MCP-1 and TGF-
protein expression by image analysis.
ELISA. Vein graft homogenates were centrifuged for
5 minutes at 10,000g. ELISA experiments on the superna-
tants for bioactive TGF- were performed following the
manufacturer’s instructions (Promega). An acid activation,
followed by neutralization, converted all latent TGF- to
bioactive TGF- and therefore enabled measurement of
total TGF- in samples, as well as bioactive TGF-. ELISA
experiments for MCP-1 were performed with Research
Diagnostics monoclonal antibody, No. RDI-RTMCP1, as
the capture antibody, and Peprotech Rabbit anti-MCP-1,
No. 500-P76, as the detection antibody. The capture anti-
body was diluted to 5 g/mL in NaCO3 0.53 g/100 ml
before being applied to the 96-well plate overnight at 4°C.
The plate was blocked with 5% Tween 20 and 5% sucrose in
PBS overnight at 4°C. Samples were transferred from the
non–acid-activated wells of the TGF- ELISA to the wells
of the MCP-1 ELISA. Because the samples were in 1
TGF- sample buffer (Promega), the standards (Research
Diagnostics, No. RDI-4012P) were also prepared in this
buffer. Samples and standards were allowed to incubate
overnight at 4°C on the 96-well plate. The detection
antibody was used at 1.25 g/mL in PBS containing 0.1%
gelatin and 0.05% Tween 20. Color was developed with
goat anti-rabbit horseradish peroxidase (Sigma) diluted
1:10,000 in PBS containing 0.1% gelatin and 3,3-tetram-
ethylbenzidine from Vector.
RNA extraction, reverse transcription, and
Q-PCR Seven vein grafts per time point were placed for
PCR analysis. Tissue was processed according to previously
published methods,25 with modifications. In brief, each
graft was excised and placed into liquid nitrogen, then
stored at 70°C until analysis. Grafts were then placed in
Trizol (Gibco BRL) and homogenized. Chloroform ex-
tractions, washes, and precipitations were performed. Pu-
rity and yields were determined with spectrophotometry.
RNA (5 g) was reverse transcribed with Superscript II
(Gibco BRL) according to the manufacturer’s instructions,
and the resulting complementary DNA was stored at
20°C until use. Yields of cDNA were quantified with
fluorescence spectrometry, and samples were diluted to 10
ng/L. For Q-PCR we pipetted three standard curves
(MCP-1, TGF-, and the housekeeping gene hypoxan-
thine phosphoribosyltransferase [HPRT]). In the same run
as the standard curves, four reactions of each sample (using
1, 1, 2, and 2 L of sample) were run for each primer set
(MCP-1, TGF-, and HPRT) on a Rotor-Gene 2000
(Corbett Research). Cycle threshold was used to determine
copies of MCP-1 or TGF- per copies of HPRT. Compar-
ing the results from reactions with 1 L of sample with the
reactions from 2 L of sample confirmed that the measure-ments were quantitative. The four estimates of MCP-1 or
TGF- copies per copy of HPRT were then averaged to
give the result for each sample. Primers were designed to
include a splice site in the amplicons as a control for the
presence of genomic DNA.
Computerized image analysis and statistics. Images
of vein graft cross-sections were captured with use of a
Nikon microscope and a Pixera color camera (Kodak).
Digital images were analyzed with MetaMorph software
(Universal Imaging). A range of red, green, and blue
intensities was defined to identify stained cells but to ex-
clude unstained cells. Once this range was determined it
was saved and used by the MetaMorph software to identify
stained cells on all sections with no further input by the
operator. The internal elastic lamina was used to delineate
media from intimal hyperplasia. The randomized design
used to assign animals to treatments and time points was
carried over into the immunohistochemical analysis so that
if there were day-to-day, or slide-to-slide, variations in
staining, the biases would average out to zero. Thus we can
be confident that any statistically significant differences we
detect are caused by the experimental treatment. Data were
log- transformed, and analysis of variance (ANOVA) was
performed to test whether the group means differed signif-
icantly from one another. Least-squares means were used to
compare pairs of groups and to identify time, treatment, or
time and treatment effects. Data are expressed as mean 
SEM and percentage.
RESULTS
Animals and grafting. Thirty grafts were used for
histologic and immunohistochemical examination, with an
overall patency rate of 90%. The condition of the grafts that
were not patent at harvest was consistent with thrombosis
of the vein graft shortly after being placed.
Drug efficacy. Splenic macrophage depletion was
used as an indicator of drug efficacy. Loss of ED1-positive
cells (monocytes and macrophages) was marked at both
time points in animals receiving intravenous Lip-Clod
treatment (Fig 1,top). These results paralleled those of
previous studies.21
Intimal hyperplasia and cellularity are reduced in
grafts treated with Lip-Clod. The progress of intimal
hyperplasia was altered in animals treated with Lip-Clod, as
reported.21 At both 1 week and 4 weeks there was a
statistically significant decrease in neointimal area develop-
ment in the Lip-Clod group compared with control groups
(Vector or PBS; Fig 2).
There was also a significant decrease in cellularity
(number of cells per 1000 m2). In the neointima at 1
week, Lip-Clod treatment significantly decreased cellular-
ity, compared with the Vector control group, but this
decrease did not quite reach significance versus the PBS
control group. At 4 weeks the reduction in cellularity of the
neointima with Lip-Clod treatment versus the PBS control
was significant. At 4 weeks the cellularity of the neointima
of the Vector group was intermediate to that of the Lip-
Clod and PBS groups (Fig 3,top). When the cellularity of
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cellularity with Lip-Clod treatment was significant com-
pared with both control groups and at both time points
(Fig 3, bottom). Although both control groups use PBS, in
the Vector treatment the PBS is contained within lipo-
somes, and these liposomes are phagocytosed by macro-
phages.
Reduced MCP-1, TGF- protein expression at 1
week in animals treated with Lip-Clod. The IgG-nega-
tive control showed low to no background staining (1%
total and neointimal area stained) in every treatment group
and at both time points. Percentage of total area staining
positive for MCP-1 was significantly decreased (P  .009)
at 1 week in the group treated with Lip-Clod compared
with PBS, and approached significance when compared
Fig 1. Immunohistochemistry of monocyte chemotac
(TGF-1) from animals treated with Lip-Clod, Vector, o
tochemical (3,3-diaminobenzidine) stain of spleen ma
monocytes) staining of the spleen section from anim
cross-sections stained for MCP-1 and TGF-, respectivel
MCP-1 and TGF- staining compared with the Vector a
reduced intimal hyperplasia and reduced hyperproliferat
counterstained with hematoxylin. Parallel staining with a
(Original magnification, 200.)with Vector (P  .055; Fig 1, middle,; Fig 4,A). A similar
trend was observed for percentage of neointimal area stain-
ing positive for MCP-1, with a significant decrease in the
Lip-Clod group compared with the PBS group (P  .01),
and a difference that approached significance when com-
pared with the Vector group (P .12; Fig 4, B). At 4 weeks
there was no significant difference in percentage of total or
neointimal area staining positive for MCP-1 among the
three groups (Fig 4, A, B).
The percentage of total area staining positive for
TGF- was significantly lower in the Lip-Clod group com-
pared with both the Vector (P  .01) and PBS (P  .006)
groups at 1 week (Fig 1, bottom; Fig 5, A). A similar trend
was seen in the percentage of neointimal area staining
positive for TGF-, with a significant decrease in TGF-
otein-1 (MCP-1) and transforming growth factor-1
sphate-buffered saline solution (PBS). Top, Immunohis-
hages shows minimal ED1-positive (macrophages and
eated with Lip-Clod. Middle and bottom, Vein graft
tions from animals treated with Lip-Clod show minimal
BS control animals. These photomicrographs also show
f the adventitia with Lip-Clod treatment. Sections were
rol antibody was used as a negative control (not shown).tic pr
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the PBS group (P  .006), and a difference that ap-
proached significance when compared with the Vector
group (P  .066; Fig 5, B). At 4 weeks there was no
difference in percentage of total area or percentage of
neointimal area staining positive for TGF- among all three
groups (Fig 5, A, B).
ELISA. To compare and contrast the changes in pro-
tein expression seen in the perianastomotic region via im-
munohistochemistry, whole grafts were homogenized and
centrifuged, and the supernatants were subjected to ELISA
for MCP-1 and TGF-. In contrast to the results of immu-
nohistochemistry, no reduction in MCP-1 protein expres-
sion was seen with Lip-Clod treatment at 1 week. At 4
weeks the Vector group demonstrated the lowest MCP-1
expression, but this was not significantly different from that
in the Lip-Clod group or the PBS group (highest expres-
sion of MCP-1; Fig 6,A). On the other hand, the 1-week
bioactive TGF- ELISA results (Fig 6, B) more closely
resembled the immunohistochemistry results, with TGF-
expression lowest in the Lip-Clod group and highest in the
PBS group. At 4 weeks the ELISA data continued to show
a significant difference between the Lip-Clod and PBS
groups, and the difference between Lip-Clod and Vector
had now reached statistical significance, whereas in the
immunohistochemistry data no significant differences were
seen in TGF- protein expression at 4 weeks among the
three groups. Total  results (not shown) mirrored those of
bioactive TGF-, except that the difference between Lip-
Clod and Vector treatment at 4 weeks did not reach
significance.
Q-PCR. After significant changes in MCP-1 and
TGF- protein expression were found at 1 week, we ana-
lyzed samples from this time point for changes in MCP-1
Fig 2. Lip-Clod attenuates intimal hyperplasia. Compa
smaller in the Lip-Clod group at both 1 and 4 weeks.
separating the neointima from the media and adventitia.
represent SEM. PBS, Phosphate-buffered saline solutionand TGF-mRNA. Message analysis with Q-PCR showed
that MCP-1 message expression at 1 week was increased in
the Lip-Clod group (P  .02) compared with the PBS
group. At 1 week there was no significant difference in
TGF- message expression among the three groups (Fig
7).
DISCUSSION
The failure rate of autologous vein grafts approaches
20% after the first post-surgical year, owing to the develop-
ment of intimal hyperplasia. This presents a significant
clinical problem for which the cause of the process is yet to
be fully described. It has been proposed that intimal hyper-
plasia is an example of aberrant wound healing due to the
presence of macrophages and myofibroblasts within the
extracellular matrix of the neointima.21 Macrophages have
a key role in wound healing and inflammatory responses.
They phagocytose cellular debris and foreign material, and
release many potent cytokines that can both attract and
stimulate other cells.2 The factors that attract monocytes
and macrophages to the site of anastomoses have not been
described, but MCP-1 is a powerful chemoattractant and
activating factor for monocytes that is released by endothe-
lial cells, SMCs, fibroblasts, and monocytes and macro-
phages, all of which are present in vein grafts.3 Once
macrophages are present in the vein wall, they can secrete
TGF-, a fibrogenic cytokine capable of regulating 	-actin
expression and myofibroblast differentiation.30,31
Previous studies by our laboratory have shown an alter-
ation of macrophage infiltration into vein grafts and a
subsequent influence on the development of intimal hyper-
plasia. This study investigates two cytokines that may be
involved in the prevention of intimal hyperplasia by macro-
phage depletion. We used liposomally encapsulated dichlo-
ith either control group, neointimal area is significantly
internal elastic lamina was traced to define the border
was derived by computerized morphometry. Error barsred w
The
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macrophages and then selectively kills the host cell by
Fig 3. Lip-Clod and reduces neointimal and total cellula
(top) and number of total cells per total cross-section
reduction with Lip-Clod treatment compared with cont
reduces neointimal and total cross-section cellularity com
(PBS). In addition, Lip-Clod treatment reduces total c
weeks. Absence of infiltrating macrophages contribute
Hematoxylin-stained nuclei were counted, and values winduction of apoptosis. In addition, this approach to mac-
rophage depletion is specific in killing macrophages.32 An-
t 1 week, number of neointimal cells per neointimal area
tom) are significantly reduced or approach significant
eatments. At 4 weeks, Lip-Clod treatment significantly
with treatment with phosphate-buffered saline solution
ection cellularity compared with Vector treatment at 4
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April 2004884 Wolff et alimals were injected 2 days before surgery with clodronate
encapsulated in liposomes. To control for any effects that
the liposomes may have on macrophages, liposomally en-
capsulated PBS was also injected; as a control for effects of
the injections, PBS alone was administered. At 1 and 4
weeks there was a significant decrease in the amount of
intimal hyperplasia in the Lip-Clod group compared with
both PBS and Vector groups. Cellularity was also signifi-
cantly decreased in the Lip-Clod group versus control
groups at both 1 week and 4 weeks. This reduction in
cellularity in the Lip-Clod group is consistent with deple-
tion of infiltrating macrophages.
Coincident with the decrease in cellularity and neoin-
timal area in the perianastomotic region, a decrease in total
cross-section and neointimal MCP-1 protein expression
occurs in the Lip-Clod group when compared with PBS at
1 week. MCP-1 comes from injured SMCs, among other
Fig 4. Total and neointimal monocyte chemotactic p
Lip-Clod–treated grafts at 1 week compared with gra
Lip-Clod treatment versus PBS at 1 week showed a sig
whereas the reduction in neointimal staining versus Vecto
Lip-Clod group remained near the same low level seen
decreased, so that at 4 weeks there was no significant diff
the entire section or in the neointima. A mean value fo
perianastomotic region of the vein graft. Results were a
n 5 for each treatment or time point.cell types. Injury at the anastomotic site causes an influx of
macrophages, which we have blocked with Lip-Clod treat-
ment. These macrophages release more MCP-1, contribut-
ing to chronic inflammation and intimal hyperplasia. Vec-
tor treatment resulted in total cross-section and neointimal
MCP-1 protein expression that was intermediate to that
seen in the Lip-Clod and PBS groups. These results suggest
that Lip-Clod treatment acts quickly to deplete macro-
phages, but that the liposomes themselves may be suppress-
ing or reversibly activating the macrophages. Hojo et al33
found, in their system, that treatment with multilamellar
liposomes depresses phagocytotic activity at 1 to 4 hours,
followed by activation of phagocytotic activity, which
peaked at 48 hours and lasted 1 week. In addition, treat-
ment with liposomes also has an effect on macrophage
production and secretion of regulatory molecules such as
cytokines, chemokines, and nitric oxide.23,34
in-1 (MCP-1) expression is significantly decreased in
eated with phosphate-buffered saline solution (PBS).
nt reduction in total and neointimal MCP-1 staining,
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actually had higher MCP-1 message levels than did the PBS
group. This increase in MCP-1 message might be a result of
Lip-Clod inhibiting macrophage migration to the vein
graft, resulting in persistent transcription of MCP-1 by the
cells of the vein graft. In a comparison of the 1-week
MCP-1 ELISA data with the 1-week MCP-1 mRNA data,
the additional mRNA seen in the Lip-Clod group did not
result in an equivalent increase in MCP-1 protein. Infiltrat-
ing macrophages carry and secrete MCP-1 protein into the
graft without need for additional mRNA. The reduction in
MCP-1 from infiltrating macrophages may be balanced by
the increase in MCP-1 transcription or translation by vein
wall cells, resulting in no net change in MCP-1. However,
the ELISA and mRNA measurements are on whole-graft
homogenates, and infiltrating macrophages are not distrib-
uted evenly throughout the graft. Rather, macrophages are
concentrated at the anastomotic sites, where suture mate-
Fig 5. Total and neointimal transforming growth factor
treated grafts at 1 week compared with grafts treated
treatment versus PBS at 1 week showed a significant r
treatment versus Vector showed a significant reduction in
reduction in neointimal area positive for TGF-. The
expression among the three treatments at 4 weeks. A me
from the perianastomotic region of the vein graft. Result
SEM; n  5 for each treatment or time point.rial or physical trauma may have initiated the production of
MCP-1. The perianastomotic region was examined by im-
munohistochemistry, and macrophage depletion had the
most dramatic effect on MCP-1 expression. Of interest,
the perianastomotic region is also where most graft failures
are seen clinically.35
A significant difference in TGF- percent total area
stained was reached against both controls at 1 week. The
neointimal expression of TGF- at 1 week was significantly
lower in the Lip-Clod group compared with the PBS
group, and approached significance when compared with
the Vector group. The 1-week ELISA data also showed a
significant reduction in TGF- with Lip-Clod versus PBS
treatment, and expression of TGF- in the Vector group
intermediate to that in the Lip-Clod and PBS groups.
However, no significant difference in TGF- message ex-
pression was seen at 1 week, although the Lip-Clod group
did have the lowest average TGF- message expression.
GF-) expression is significantly decreased in Lip-Clod–
phosphate-buffered saline solution (PBS). Lip-Clod
ion in total and neointimal TGF- staining. Lip-Clod
area positive for TGF-, and approached significance for
s no difference in TGF- total or neointimal protein
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April 2004886 Wolff et alFig 6. Enzyme-linked immunoassay of whole-graft lysates shows a reduction in transforming growth factor- (TGF-)
expression with Lip-Clod treatment, but no change in monocyte chemotactic protein-1 (MCP-1) expression. A, No
difference in MCP-1 expression is seen among the three treatments at 1 week. At 4 weeks MCP-1 expression is highest
in the phosphate-buffered saline solution (PBS) group and lowest in the Vector group, but these differences did not
reach statistical significance. B, At 1 week TGF- expression is significantly reduced with Lip-Clod versus PBS. At 4
weeks the reduction in TGF- expression is significant versus both control groups.
le of s
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including myofibroblasts. The reduction in TGF- protein
expression seen by immunohistochemistry at the perianas-
tomotic site is likely due to the reduction in infiltrating
macrophages carrying TGF- to this region, just as the
reduction in MCP-1 was attributed to a lack in infiltrating
macrophages. And, just as the difference between groups
was reduced at 4 weeks as the numbers of macrophages in
the PBS and Vector groups tapered off, no significant
differences were seen at 4 weeks for TGF- expression with
immunohistochemistry. However, by removing the initial
inrush of macrophages, Lip-Clod treatment may have re-
duced or removed the stimulus, from the macrophages
themselves or in combination with cells of the vessel wall,
for the transformation of fibroblasts and SMCs into myofi-
broblasts. Because myofibroblasts proliferate and migrate,
inhibiting their initial transformation would have a lasting
effect throughout the graft, such as the reduction in TGF-
seen at 1 and 4 weeks with ELISA.
Reducing the cytokines in the vein grafts early after
grafting influences the development of intimal hyperplasia
later. Macrophages may be the principal cell releasing MCP-1,
thereby recruiting more monocytes and macrophages to the
site of injury and contributing to the chronic nature of intimal
hyperplasia. Activated macrophages can secrete TGF-, which
is thought to regulate 	-actin expression and myofibroblast
differentiation.30,31 Myofibroblasts are synthetic cells in-
Fig 7. Grafts from animals treated with liposomally enca
chemotactic protein-1 (MCP-1) than do animals treated
in mRNA for TGF-. Grafts were homogenized in T
transcription to cDNA. Copy number of gene of interes
polymerase chain reaction, on the basis of threshold cycvolved in the production of extracellular matrix. Deposition of
this matrix within vein grafts is thought to be responsible for
neointimal thickening. Therefore the marked decrease in
MCP-1 and TGF- expression at 1 week owing to macro-
phage depletion may alter the differentiation of fibroblasts
into myofibroblasts, resulting in decreased intimal hyperplasia
at 4 weeks. Future studies will attempt to identify and quantify
fibroblasts and myofibroblasts in the Lip-Clod group and
further explore the role of TGF- in myofibroblast cell differ-
entiation.
Glen Leverson, PhD, Department of Surgery Biostatis-
tics Office, assisted in the statistical analysis. We also thank
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